PolyPeptide delivers strong revenue growth and marked improvement in profitability
Ad hoc announcements pursuant to Art. 53 LR
Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 and guidance for 2026:
- Revenue of EUR 389.3 million, representing growth of 15.6% versus prior year; at constant currency rates, growth was slightly higher at 16.0%
- EBITDA of EUR 46.8 million versus EUR 25.4 million in 2024 (+84.4%) with margin increase of 4.5 percentage points to 12.0% versus 7.5% in 2024, primarily reflecting higher production volumes, improved operational performance and product mix
- Net cash flows from operating activities of EUR 77.5 million versus EUR 89.4 million in 2024, driven by increased profitability and preparations for future growth with customer support
- Capital expenditures of EUR 110.0 million, 28.2% of revenue, versus EUR 87.8 million and 26.1% of revenue in 2024, reflecting investments across PolyPeptide’s global manufacturing site network to meet strong customer demand
- The ramp-up of the new large-scale SPPS facility in Belgium was successfully completed in 2025, achieving target utilization rate at year-end
- PolyPeptide remains well positioned to meet its mid-term outlook to double revenue reported for 2023 by 2028, with the EBITDA margin expected to approach 25% by 2028, and capital expenditures of 15% to 20% of revenue over the mid-term horizon and on average to ensure capacity also beyond 2028
- Guidance 2026: Revenue growth of 20% to 25% versus 2025, at constant currency rates. EBITDA margin expected to continue to rise, reaching mid- to high-teens. Capital expenditures expected to be in line with the mid-term outlook of 15% to 20% of revenue
- The audio webcast and conference call will take place today at 9:00 am CET (for access details, please see page 5)
Juan Jose Gonzalez, CEO of PolyPeptide: “In 2025, we delivered strong financial progress, with revenue increasing by 16% at constant currency rates and EBITDA rising by 84%. These improvements were driven by robust peptide metabolic demand, better operational execution, and disciplined investment across our global network. With strong customer demand and clear visibility into upcoming programs, we remain confident in our ability to continue advancing toward our midterm targets.”
[…]